← Eichor
Condition: Melanoma Stage Ii Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Melanoma Stage Ii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Tebentafusp for Uveal Melanoma
Phase 2 · 2 location(s) · Thomas Jefferson University · NCT06414590A Study of ST-1898 for Unresectable or Metastatic Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359860BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
Phase 2 · 1 location(s) · Oslo University Hospital · NCT06651151A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
Phase 2 · 1 location(s) · Fudan University · NCT06889610Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion
Phase 1/Phase 2 · 4 location(s) · Vastra Gotaland Region · NCT03685890Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Phase 1/Phase 2 · 9 location(s) · NuCana plc · NCT03829254Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06961357Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Phase 2 · 1 location(s) · Melanoma Institute Australia · NCT06999980A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
Phase 2 · 1 location(s) · A.J.M. van den Eertwegh · NCT04126876Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05830058Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tu
Phase 2 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT06630611Modified Vaccine for High Risk or Low Residual Melanoma Patients
Phase 1/Phase 2 · 1 location(s) · Hadassah Medical Organization · NCT01898039Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Phase 2 · 3 location(s) · Diwakar Davar · NCT06070012A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.
Phase 2 · 1 location(s) · Universitair Ziekenhuis Brussel · NCT07448831Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Phase 2 · 1 location(s) · Stanford University · NCT06712927Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT07170293Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
Phase N/A · 1 location(s) · John Kirkwood · NCT06599619OH2 Injection in Combination With HX008 for Melanoma.
Phase 1/Phase 2 · 1 location(s) · Binhui Biopharmaceutical Co., Ltd. · NCT04616443GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamou
Phase 2 · 1 location(s) · Providence Health & Services · NCT05913388RAPA-201 Therapy of Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Rapa Therapeutics LLC · NCT05144698A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
Phase 1/Phase 2 · 1 location(s) · University of Louisville · NCT01638676Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma
NA · 5 location(s) · Azienda Ospedaliera di Perugia · NCT07050940Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Phase 2 · 2 location(s) · University of California, San Francisco · NCT04598009Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
Phase 3 · 26 location(s) · Uppsala University · NCT06488482Explorative Study on Addition of High-fiber Dried Chicory Root in Patients With an Intermediate to High-risk Cutaneous M
NA · 1 location(s) · University Medical Center Groningen · NCT07206017A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma
NA · 20 location(s) · Uppsala University · NCT03116412Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Phase 1/Phase 2 · 6 location(s) · The Netherlands Cancer Institute · NCT06240143
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.